EngVIPO Engineering Vascularized Implants for Personalised Osteochondral Tissue Regeneration: From medical imaging to pre-clinical validation
- Coordinator
- Universidade Do Minho, Portugal
- Runs
- 1 January 2025 to 31 December 2028
- Status
- Running
- EU funding
- €1.3m
- Total cost
- —
- Partners
- 8 organisations in 6 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101183041
What the project is doing
In the project's own words, from its summary on CORDIS.
Osteochondral Injuries (OCI) is a challenging yet common clinical problem for orthopaedic surgeons worldwide and is associated with multiple clinical scenarios ranging from trauma to osteonecrosis. Strategies for functional tissue regeneration at still far from the clinics and should endeavour to heal the subchondral bone and joint interface and hyaline cartilage. Enhancing the understanding of the mechanisms that underlie OCI holds the potential to unlock ground-breaking advancements in therapeutic interventions.
EngVIPO tackles current challenges in the realm of biofabricated patient-specific implants with enhanced vascularity and functionality, concerning scientific expertise and collaborations with renowned institutions for OC tissue engineering, within the interdisciplinary domains of 3D computational modelling, advanced manufacturing, 3D in vitro models, and nanotechnology, and boosting clinical translation of the tissue engineered products.
The project is focused on catapult knowledge exchange and create research synergies on the development of innovative biomaterials and bioinks, emerging technologies, biobanks and personalized medicine, for the complete regeneration and establishment of normal function of injured/diseased OC tissue. This will range from advanced biomaterials/scaffolds incorporating bioactive ions with osteogenic function, implementation of innovative manufacturing technologies, spheroids/organoids integrated into microfluidics, therapeutic biologicals and biobanks, in silico modelling, in vitro immunocompatiblity, to in vivo evaluation.
Such innovative approach represents a significant advancement in the field of orthopedics, leading to improved participation of biobanks towards the development of advanced implants and patient outcomes, and setting new standards for personalized implant solutions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade Do Minho | Braga | Portugal | Coordinator |
| Sun Yat-Sen University | Guangzhou | China | Associatedpartner |
| Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Erlangen | Germany | Participant |
| Universidad De Granada | Granada | Spain | Participant |
| Akademia Gorniczo-Hutnicza Im. Stanislawa Staszica W Krakowie | Krakow | Poland | Participant |
| Ti-Com Spolka Z Ograniczona Odpowiedzialnoscia | Olsztyn | Poland | Participant |
| Association for the Advancement of Tissue Engineering and Cell Based Technologies & Therapies | Caldas Das Taipas Caldelas | Portugal | Participant |
| Univerzitet U Kragujevcu | Kragujevac | Serbia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI